February 2017

15
Feb

Ichor Therapeutics announces series A offering for LYSOCLEAR to move first SENS therapy into the clinic

February 15th, 2017 LAFAYETTE, NY: Today, Ichor Therapeutics, a biotechnology company that focuses on developing drugs for age-related diseases, announced a series A offering to bring its LYSOCLEAR product for age-related macular degeneration and Stargardt’s macular degeneration through Phase I clinical trials. This product would be the first clinical candidate based on the SENS paradigm, pioneered by biomedical gerontologist Dr.

Read more